| Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study |
96 |
| Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review |
58 |
| Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up |
50 |
| Rapid review: radiomics and breast cancer |
29 |
| Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) |
29 |
| Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals |
28 |
| Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy |
28 |
| Clinical implications of germline mutations in breast cancer: TP53 |
26 |
| Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study |
25 |
| Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers |
25 |
| Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study |
23 |
| Surgical trends in breast cancer: a rise in novel operative treatment options over a 12year analysis |
22 |
| Social determinants of breast cancer risk, stage, and survival |
22 |
| Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness |
22 |
| Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010 |
22 |
| Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature |
21 |
| A pilot study of a breast surgery Enhanced Recovery After Surgery (ERAS) protocol to eliminate narcotic prescription at discharge |
20 |
| Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review |
20 |
| Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer |
20 |
| Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set |
19 |
| Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial |
19 |
| Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer |
19 |
| Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life |
19 |
| Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study |
18 |
| Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement |
18 |
| Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy |
18 |
| Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer |
18 |
| High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer |
18 |
| Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial |
17 |
| MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis |
17 |
| The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer |
17 |
| Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors |
17 |
| Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer |
17 |
| Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting |
17 |
| A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients |
16 |
| Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer |
16 |
| Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial |
16 |
| Male breast cancer: a disease distinct from female breast cancer |
16 |
| The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review |
16 |
| Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study |
15 |
| Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients |
15 |
| Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer |
15 |
| GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer |
14 |
| Mutant p53 in breast cancer: potential as a therapeutic target and biomarker |
14 |
| Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial |
14 |
| High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival |
14 |
| CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials |
14 |
| Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance |
14 |
| Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013 |
13 |
| Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer |
13 |
